Skip to main content
Alan Ashworth on Muck Rack

Alan Ashworth

Verified
Akron
As seen in: Akron Beacon Journal, USA Today Co., Medium, MSN, Yahoo Life, Color Research & Application, Golfweek, Nature, USA Today, Yahoo News, Yahoo Finance, U.S. News and World Report and
News writer for the Akron Beacon Journal covering southern Summit County. Reach him at 330-996-3859 or aashworth@gannett.com.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alan

Contact Alan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding

|
By Jingkun Zeng, Zhiyuan Cheng, Huadong Chen, Zhaojun Wang, Jared Thompson, Kadin T. Crosby, Hesong Han, Arushi Singhal, Wayne Ngo, Chenglong Xia, Daniel Rosas-Rivera, Zeyuan Zhang, Ying Mao, Morgan E. Diolaiti, Giselle Lee, John F. X. Diffley, Yixuan Song, Longhui Qiu, Nathan M. Krah, Niren Murthy, Ryan Jackson, Yang Liu Verified, Alan Ashworth Verified, Jennifer Doudna, Min Hyung Kang
| Nature Verified
Abstract Genetic mutations that drive cancer often occur in tumor suppressor proteins, including the p53 transcription factor which is altered in ~40-50% of cases1,2. However, current therapies fail to target most such mutations because the mutant proteins typically lack defined drug-binding pockets, and restoring the endogenous function has proven challenging.
Open in Who Shared Issue with article?

Two decades of PARP inhibitor synthetic lethality in cancer

|
By Christopher Lord Verified, Andrew Tutt, Alan Ashworth Verified
| Nature Verified
Abstract Two decades ago, two papers in Nature described how PARP inhibitors selectively killed cells deficient in the BRCA1 or BRCA2 tumour suppressor genes, observations that led to the first clinically approved treatment of a cancer with a targeted therapy selected based on a germline biomarker.
Open in Who Shared Issue with article?

Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells | British Journal of Cancer

|
By Rahul Kumar, James Campbell, Inger Brandsma, Helen Pemberton, Fredrik Wallberg, Kinga Nagy, Beata G. Vertessy, Artur A. Serebrenik, Reuben S. Harris, Stephen Pettitt, Alan Ashworth Verified, Christopher Lord Verified, Jenni Nikkilä, Ildikó Scheer, Valentina Monni
| Nature Verified
Correction to: British Journal of Cancer https://doi.org/10.1038/bjc.2017.133, published online 23 May 2017 Following publication of the article, an error was noted in Figure 1F: The data in Fig. 1F for “293-A3B-p53 cells” were mistakenly introduced; the correct data are now displayed in Fig. 1F. About this article Nikkilä, J., Kumar, R., Campbell, J. et al.
Open in Who Shared Issue with article?
See all 1,145 licensed articles (2,013 Total)